Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02927262
Title	A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Astellas Pharma Global Development, Inc.
Indications	acute myeloid leukemia
Therapies	Gilteritinib
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN